{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:22:51Z","timestamp":1789381371782,"version":"build-2803163510"},"reference-count":93,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"DOI":"10.3201\/eid0808.010516","type":"journal-article","created":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T17:58:41Z","timestamp":1334858321000},"page":"833-841","source":"Crossref","is-referenced-by-count":127,"title":["Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons"],"prefix":"10.3201","volume":"8","author":[{"given":"Arturo","family":"Casadevall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","published-online":{"date-parts":[[2002,8]]},"reference":[{"key":"key-10.3201\/eid0808.010516-201204190400-R1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.11.1.1","article-title":"The use of licensed vaccines for active immunization of the immunocompromised host.","volume":"11","author":"Pirofski","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"key-10.3201\/eid0808.010516-201204190400-R2","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/AAC.38.8.1695","article-title":"\"Serum therapy\" revisited: animal models of infection and the development of passive antibody therapy.","volume":"38","author":"Casadevall","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid0808.010516-201204190400-R3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/clinids\/21.1.150","article-title":"Return to the past: the case for antibody-based therapies in infectious diseases.","volume":"21","author":"Casadevall","year":"1995","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid0808.010516-201204190400-R4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nbt0901-819","article-title":"Monoclonal antibodies and the clinic.","volume":"19","author":"Reichert","year":"2001","journal-title":"Nat Biotechnol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R5","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.281.18.1735","article-title":"Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.","volume":"281","author":"Inglesby","year":"1999","journal-title":"JAMA"},{"key":"key-10.3201\/eid0808.010516-201204190400-R6","first-page":"188","article-title":"Channels formed in phospholipid bilayer membranes by diphtheria, tetanus, botulinum and anthrax toxin.","volume":"84","author":"Finkelstein","year":"1990","journal-title":"J Physiol (Paris)"},{"key":"key-10.3201\/eid0808.010516-201204190400-R7","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","article-title":"Search for correlates of protective immunity conferred by anthrax vaccine.","volume":"69","author":"Reuveny","year":"2001","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R8","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax.","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"key":"key-10.3201\/eid0808.010516-201204190400-R9","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1016\/S0264-410X(01)00197-9","article-title":"Passive transfer of protection against Bacillus anthracis infection in a murine model.","volume":"19","author":"Beedham","year":"2001","journal-title":"Vaccine"},{"key":"key-10.3201\/eid0808.010516-201204190400-R10","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1128\/IAI.65.12.5171-5175.1997","article-title":"Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.","volume":"65","author":"Little","year":"1997","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1128\/IAI.70.2.544-550.2002","article-title":"Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive protection.","volume":"70","author":"Kobiler","year":"2002","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R12","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/00221287-147-6-1677","article-title":"The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.","volume":"147","author":"Welkos","year":"2001","journal-title":"Microbiology"},{"key":"key-10.3201\/eid0808.010516-201204190400-R13","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jama.1941.02820140018005","article-title":"The treatment of anthrax.","volume":"14","author":"Lucchesi","year":"1941","journal-title":"JAMA"},{"key":"key-10.3201\/eid0808.010516-201204190400-R14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.295.5556.777a","article-title":"'Borrowed immunity' may save future victims.","volume":"295","author":"Enserink","year":"2002","journal-title":"Science"},{"key":"key-10.3201\/eid0808.010516-201204190400-R15","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1128\/IAI.67.6.2957-2963.1999","article-title":"Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.","volume":"67","author":"Cirino","year":"1999","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R16","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon: medical and public health management.","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"key-10.3201\/eid0808.010516-201204190400-R17","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/0002-9343(84)90988-4","article-title":"Equine antitoxin use and other factors that predict outcome in Type A foodborne botulism.","volume":"76","author":"Tacket","year":"1984","journal-title":"Am J Med"},{"key":"key-10.3201\/eid0808.010516-201204190400-R18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/clinids\/23.2.337","article-title":"Experience with the use of an investigational F(ab\u00b4)2 heptavalent bolulism immune globulin of equine origin during an outbreak of Type E botulism in Egypt.","volume":"23","author":"Hibbs","year":"1996","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid0808.010516-201204190400-R19","doi-asserted-by":"crossref","unstructured":"Franz DR, Pitt LM, Clayton MA. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalational botulism. In: Das-Gupta BR, editor. Botulinum and tetanus neurotoxins: neurotransmission and biological aspects. New York: Plenum Press; 1993. p. 473\u20136.","DOI":"10.1007\/978-1-4757-9542-4_52"},{"key":"key-10.3201\/eid0808.010516-201204190400-R20","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1002\/(SICI)1099-1263(199912)19:1+<S35::AID-JAT612>3.0.CO;2-9","article-title":"Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalational model.","volume":"19","author":"Gelzleichter","year":"1999","journal-title":"J Appl Toxicol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1432-1033.1994.tb19926.x","article-title":"Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes.","volume":"219","author":"Cenci Di Bello","year":"1994","journal-title":"Eur J Biochem"},{"key":"key-10.3201\/eid0808.010516-201204190400-R22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1089\/hyb.1997.16.447","article-title":"Identification and characterization of a neutralizing monoclonal antibody against botulinum neurotoxin serotype F, following vaccination with active toxin.","volume":"16","author":"Brown","year":"1997","journal-title":"Hybridoma"},{"key":"key-10.3201\/eid0808.010516-201204190400-R23","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1128\/IAI.69.1.570-574.2001","article-title":"High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.","volume":"69","author":"Pless","year":"2001","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R24","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1128\/AEM.67.7.3201-3207.2001","article-title":"Characterization of neutralizing antibodies and identification of neutralizing mimics on the Clostridium botulinum neurotoxin type A.","volume":"67","author":"Wu","year":"2001","journal-title":"Appl Environ Microbiol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R25","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1128\/IAI.69.10.6511-6514.2001","article-title":"Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.","volume":"69","author":"Mullaney","year":"2001","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0041-0101(00)00189-6","article-title":"Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin.","volume":"39","author":"Sheridan","year":"2001","journal-title":"Toxicon"},{"key":"key-10.3201\/eid0808.010516-201204190400-R27","first-page":"651","article-title":"Antibody-mediated protection against Brucella abortus in BALB\/c mice at successive periods after infection: variation between virulent strain 2308 and attenuated vaccine strain 19.","volume":"82","author":"Elzer","year":"1994","journal-title":"Immunology"},{"key":"key-10.3201\/eid0808.010516-201204190400-R28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0928-8244(94)90038-8","article-title":"Protection and suppression of the humoral response in mice mediated by a monoclonal antibody against the M epitope of Brucella.","volume":"8","author":"Vizcaino","year":"1994","journal-title":"FEMS Immunol Med Microbiol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R29","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/BF00173981","article-title":"In vitro and in-vivo immunobiological properties of murine monoclonal anti-Brucella antibodies.","volume":"40","author":"Adone","year":"1994","journal-title":"Appl Microbiol Biotechnol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R30","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1128\/IAI.60.1.312-315.1992","article-title":"Protection against Brucella melitensis or Brucella abortus in mice with immunoglobulin G (IgG), IgA, and IgM monoclonal antibodies specific for a common epitope shared by the Brucella A and M smooth lipopolysaccharides.","volume":"60","author":"Cloeckaert","year":"1992","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1099\/00222615-43-5-344","article-title":"Outer-membrane protein- and rough lipopolysaccharide-specific monoclonal antibodies protect mice against Brucella ovis.","volume":"43","author":"Bowden","year":"1995","journal-title":"J Med Microbiol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1286-4579(00)00317-8","article-title":"Identification of protective outer membrane antigens of Brucella ovis by passive immunization of mice with monoclonal antibodies.","volume":"2","author":"Bowden","year":"2000","journal-title":"Microbes Infect"},{"key":"key-10.3201\/eid0808.010516-201204190400-R33","first-page":"422","article-title":"Search for correlates of resistance to virulent challenge in mice immunized with Coxiella burnetii.","volume":"21","author":"Kazar","year":"1977","journal-title":"Acta Virol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1128\/IAI.31.2.641-645.1981","article-title":"Role of antibody in Coxiella burnetii infection.","volume":"31","author":"Humpres","year":"1981","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/IAI.43.1.253-256.1984","article-title":"Kirkpatrick tL, Rowatt JD, Baca OG. Antibody-dependent cellular cytotoxicity of Coxiella burnetii-infected J774 macrophage target cells.","volume":"43","author":"Koster","year":"1984","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R36","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1001\/jama.283.17.2281","article-title":"Plague as a biological weapon: medical and public health management. Working group on civilian biodefense.","volume":"283","author":"Inglesby","year":"2000","journal-title":"JAMA"},{"key":"key-10.3201\/eid0808.010516-201204190400-R37","unstructured":"Strong RP. Plague. Stitt's diagnosis, prevention and treatment of tropical diseases. Philadelphia: The Blakiston Company; 1944. p. 651\u2013710."},{"key":"key-10.3201\/eid0808.010516-201204190400-R38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1365-2249.1999.00859.x","article-title":"An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model.","volume":"116","author":"Williamson","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1574-695X.1999.tb01229.x","article-title":"The SCID\/Beige mouse as a model to investigate protection against Yersinia pestis.","volume":"23","author":"Green","year":"1999","journal-title":"FEMS Immunol Med Microbiol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4269\/ajtmh.1997.56.471","article-title":"Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis.","volume":"56","author":"Anderson","year":"1997","journal-title":"Am J Trop Med"},{"key":"key-10.3201\/eid0808.010516-201204190400-R41","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","article-title":"Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.","volume":"281","author":"Henderson","year":"1999","journal-title":"JAMA"},{"key":"key-10.3201\/eid0808.010516-201204190400-R42","unstructured":"van Rooyen CE, Rhodes AJ. Virus diseases of man. New York: Thomas Nelson & Sons; 1948."},{"key":"key-10.3201\/eid0808.010516-201204190400-R43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S0140-6736(00)70632-5","article-title":"Asiatic smallpox.","volume":"1","author":"Wilkinson","year":"1943","journal-title":"Lancet"},{"key":"key-10.3201\/eid0808.010516-201204190400-R44","first-page":"30","article-title":"Treatment of smallpox with an antigen-antibody mixture.","volume":"77","author":"Panja","year":"1942","journal-title":"Ind Med Gaz"},{"key":"key-10.3201\/eid0808.010516-201204190400-R45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1423-0410.1976.tb02224.x","article-title":"The efficacy of vaccinial immune globulin.","volume":"31","author":"Ferry","year":"1976","journal-title":"Vox Sang"},{"key":"key-10.3201\/eid0808.010516-201204190400-R46","first-page":"41","article-title":"The use of vaccinia hyperimmune glamma-globulin in the prophylaxis of smallpox.","volume":"25","author":"Kempe","year":"1961","journal-title":"Bull World Health Organ"},{"key":"key-10.3201\/eid0808.010516-201204190400-R47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"key":"key-10.3201\/eid0808.010516-201204190400-R48","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1001\/jama.285.21.2763","article-title":"Tularemia as a biological weapon: medical and public health management.","volume":"285","author":"Dennis","year":"2001","journal-title":"JAMA"},{"key":"key-10.3201\/eid0808.010516-201204190400-R49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-194002000-00001","article-title":"Tularemia: a summary of certain aspects of the disease including methods for early diagnosis and the results of serum treatment in 600 patients.","volume":"19","author":"Foshay","year":"1940","journal-title":"Medicine"},{"key":"key-10.3201\/eid0808.010516-201204190400-R50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00000441-199408000-00003","article-title":"Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine.","volume":"308","author":"Drabick","year":"1994","journal-title":"Am J Med Sci"},{"key":"key-10.3201\/eid0808.010516-201204190400-R51","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1016\/S0264-410X(01)00189-X","article-title":"Role of antibody to lipopolysaccharide in protection against low- and high-virulence strrains of Francisella tularensis.","volume":"19","author":"Fulop","year":"2001","journal-title":"Vaccine"},{"key":"key-10.3201\/eid0808.010516-201204190400-R52","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1128\/IAI.62.8.3129-3137.1994","article-title":"Transfer of immunity against lethal murine Francisella infection by specific antibody depends of host gamma interferon and T cells.","volume":"62","author":"Rhinehart-Jones","year":"1994","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF01320552","article-title":"An attenuated variant of Eastern encephalitis virus: biological properties and protection induced in mice.","volume":"47","author":"Brown","year":"1975","journal-title":"Arch Virol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/0042-6822(88)90659-9","article-title":"In vitro mechanisms of monoclonal antibody neutralization of alphaviruses.","volume":"165","author":"Roehrig","year":"1988","journal-title":"Virology"},{"key":"key-10.3201\/eid0808.010516-201204190400-R55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0042-6822(91)90775-7","article-title":"Synthetic peptides of the E2 glycoprotein of Venezuelan equine encephalomyelitis virus: II. Antibody to the amino terminus protects animals by limiting viral replication.","volume":"185","author":"Hunt","year":"1991","journal-title":"Virology"},{"key":"key-10.3201\/eid0808.010516-201204190400-R56","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0264-410X(95)93315-Z","article-title":"Localization of a protective epitope on a Venezuelan equine encephalomyelitis (VEE) virus peptide that protects mice from both epizootic and enzootic VEE virus challenge and it immunogenic in horses.","volume":"13","author":"Hunt","year":"1995","journal-title":"Vaccine"},{"key":"key-10.3201\/eid0808.010516-201204190400-R57","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1086\/514298","article-title":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.","volume":"179","author":"Mupapa","year":"1999","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid0808.010516-201204190400-R58","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0140-6736(79)92335-3","article-title":"Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome.","volume":"2","author":"Maiztegui","year":"1979","journal-title":"Lancet"},{"key":"key-10.3201\/eid0808.010516-201204190400-R59","first-page":"435","article-title":"Lassa immune serum.","volume":"55","author":"Clayton","year":"1977","journal-title":"Bull World Health Organ"},{"key":"key-10.3201\/eid0808.010516-201204190400-R60","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1128\/JVI.75.10.4649-4654.2001","article-title":"Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.","volume":"75","author":"Gupta","year":"2001","journal-title":"J Virol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R61","first-page":"135","article-title":"Passive immunizatio of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses.","volume":"11","author":"Jahrling","year":"1996","journal-title":"Arch Virol Suppl"},{"key":"key-10.3201\/eid0808.010516-201204190400-R62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/149.3.420","article-title":"Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys.","volume":"149","author":"Jahrling","year":"1984","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid0808.010516-201204190400-R63","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/IAI.44.2.528-533.1984","article-title":"Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain.","volume":"44","author":"Jahrling","year":"1984","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R64","doi-asserted-by":"publisher","first-page":"S218","DOI":"10.1086\/514294","article-title":"Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.","volume":"179","author":"Kudoyarova-Zubavichene","year":"1999","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid0808.010516-201204190400-R65","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1128\/JVI.75.5.2324-2330.2001","article-title":"Infectivity-enhancing antibodies to Ebola virus glycoprotein.","volume":"75","author":"Takada","year":"2001","journal-title":"J Virol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R66","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(84)90299-X","article-title":"Importance of dose of neutralizing antibodies in treatment of Argentine haemorrhagic fever with immune serum.","volume":"2","author":"Enria","year":"1984","journal-title":"Lancet"},{"key":"key-10.3201\/eid0808.010516-201204190400-R67","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus.","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"key":"key-10.3201\/eid0808.010516-201204190400-R68","first-page":"1113","article-title":"Ueber das Zustandekommen der Diptherie-Immunit\u00e4t und der Tetanus-Immunit\u00e4t bei Thieren.","volume":"49","author":"Behring","year":"1890","journal-title":"Deutch Med Woch"},{"key":"key-10.3201\/eid0808.010516-201204190400-R69","first-page":"895","article-title":"Diphtheria, tetanus, and pertussis: Guidelines for vaccine prophylaxis and other preventive measures.","volume":"34","author":"Centers for Disease Control and Prevention","year":"1985","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.3201\/eid0808.010516-201204190400-R70","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/15563657808988249","article-title":"Medical toxicologist's notebook: snakebite treatment and international antivenin index.","volume":"13","author":"Rappolt","year":"1978","journal-title":"Clin Toxicol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R71","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0272-2712(18)30023-4","article-title":"Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents.","volume":"21","author":"Madsen","year":"2001","journal-title":"Clin Lab Med"},{"key":"key-10.3201\/eid0808.010516-201204190400-R72","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1089\/hyb.1994.13.417","article-title":"Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo.","volume":"13","author":"Lemley","year":"1994","journal-title":"Hybridoma"},{"key":"key-10.3201\/eid0808.010516-201204190400-R73","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.1073\/pnas.92.14.6294","article-title":"Staphylococcal enterotoxins bind H-2Db molecules on macrophages.","volume":"92","author":"Beharra","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.3201\/eid0808.010516-201204190400-R74","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF00919271","article-title":"Half-life of the maternal IgG1 allotype in infants.","volume":"13","author":"Sarvas","year":"1993","journal-title":"J Clin Immunol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R75","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev.bioeng.2.1.339","article-title":"Antibody engineering.","volume":"2","author":"Maynard","year":"2000","journal-title":"Annu Rev Biomed Eng"},{"key":"key-10.3201\/eid0808.010516-201204190400-R76","first-page":"172","article-title":"Therapeutic antibody production technologies: molecules, applications, expression and purification.","volume":"4","author":"Humphreys","year":"2001","journal-title":"Curr Opin Drug Discov Devel"},{"key":"key-10.3201\/eid0808.010516-201204190400-R77","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1006\/clim.1999.4768","article-title":"Passive antibody therapies: progress and continuing challenges.","volume":"93","author":"Casadevall","year":"1999","journal-title":"Clin Immunol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R78","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1128\/IAI.68.4.2187-2195.2000","article-title":"Antibody-mediated elimination of the obligate intracellular bacterial pathogen Erhlichia chaffeensis during active infection.","volume":"68","author":"Winslow","year":"2000","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R79","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1086\/515688","article-title":"A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis.","volume":"178","author":"Fleuridor","year":"1998","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid0808.010516-201204190400-R80","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.4049\/jimmunol.163.8.4087","article-title":"Cutting edge: paradigm revisited: antibody provides resistance to Listeria infection.","volume":"163","author":"Edelson","year":"1999","journal-title":"J Immunol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R81","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1128\/IAI.63.7.2714-2719.1995","article-title":"Antibody response that protects against disseminated candidiasis.","volume":"63","author":"Han","year":"1995","journal-title":"Infect Immun"},{"key":"key-10.3201\/eid0808.010516-201204190400-R82","doi-asserted-by":"publisher","first-page":"15688","DOI":"10.1073\/pnas.95.26.15688","article-title":"A monoclonal antibody recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival.","volume":"95","author":"Teitelbaum","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.3201\/eid0808.010516-201204190400-R83","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1086\/317930","article-title":"Intervention with Shiga toxin (Stx) antibody after infection by STx-producing Escherichia coli.","volume":"183","author":"Matise","year":"2001","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid0808.010516-201204190400-R84","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jama.235.1.42","article-title":"Serologic therapy of tetanus in the United States.","volume":"235","author":"Blake","year":"1976","journal-title":"JAMA"},{"key":"key-10.3201\/eid0808.010516-201204190400-R85","doi-asserted-by":"crossref","first-page":"926","DOI":"10.7326\/0003-4819-113-12-926","article-title":"Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS.","volume":"113","author":"Frickhofen","year":"1990","journal-title":"Ann Intern Med"},{"key":"key-10.3201\/eid0808.010516-201204190400-R86","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/00007890-199712270-00037","article-title":"Parvovirus B19 infection-related complications in renal transplant recipients. Treatment with intravenous immunoglobulin.","volume":"64","author":"Moudgil","year":"1997","journal-title":"Transplantation"},{"key":"key-10.3201\/eid0808.010516-201204190400-R87","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/bmj.323.7320.1017","article-title":"Prophylactic treatment of anthrax with antibiotics.","volume":"323","author":"Hart","year":"2001","journal-title":"BMJ"},{"key":"key-10.3201\/eid0808.010516-201204190400-R88","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/0264-410X(95)00256-Z","article-title":"Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model.","volume":"14","author":"Devi","year":"1996","journal-title":"Vaccine"},{"key":"key-10.3201\/eid0808.010516-201204190400-R89","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1086\/314779","article-title":"Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis.","volume":"179","author":"Han","year":"1999","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid0808.010516-201204190400-R90","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4049\/jimmunol.151.1.466","article-title":"Immunotherapy with human monoclonal antibodies.","volume":"151","author":"Lang","year":"1993","journal-title":"J Immunol"},{"key":"key-10.3201\/eid0808.010516-201204190400-R91","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1086\/514588","article-title":"Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy.","volume":"26","author":"Norrby-Teglund","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid0808.010516-201204190400-R92","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1365-3148.2001.00288.x","article-title":"Intravenous immunoglobulin: regulatory perspectives on use and supply.","volume":"11","author":"Farrugia","year":"2001","journal-title":"Transfus Med"},{"key":"key-10.3201\/eid0808.010516-201204190400-R93","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1128\/CDLI.1.6.613-619.1994","article-title":"Human immunoglobulins for intravenous use and hepatitis C viral transmission.","volume":"1","author":"Slade","year":"1994","journal-title":"Clin Diagn Lab Immunol"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/8\/8\/01-0516_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T02:41:17Z","timestamp":1732588877000},"score":1,"resource":{"primary":{"URL":"http:\/\/wwwnc.cdc.gov\/eid\/article\/8\/8\/01-0516_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":93,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2002,8]]}},"URL":"https:\/\/doi.org\/10.3201\/eid0808.010516","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8]]}}}